T1	Organism 3646 3651	human
T2	Disease 3652 3681	triple-negative breast cancer
T3	Disease 3694 3716	adjacent breast tissue
T5	Disease 3791 3805	normal omentum
T6	OrganismPart 3668 3674	breast
T7	OrganismPart 3798 3805	omentum
T9	ReductionReagent 6756 6770	dithiothreitol
T10	AlkylationReagent 6884 6897	iodoacetamide
T11	CleavageAgent 7245 7250	Lys-C
T12	CleavageAgent 7348 7355	trypsin
T13	Separation 8328 8369	reversed-phase HPLC using an EASY-nLC1000
T14	AcquisitionMethod 8949 8963	data-dependent
T15	Sex 4137 4142	women
T16	IonizationType 8556 8572	nanoelectrospray
T17	Instrument 8581 8608	QExactive mass spectrometer
T18	FractionationMethod 9363 9390	high-pH reversed-phase HPLC
T19	NumberOfFractions 9787 9799	15 fractions
T20	GradientTime 8532 8539	140 min
T21	GradientTime 10082 10089	140 min
T22	PrecursorMassTolerance 10361 10367	10 ppm
T23	FragmentMassTolerance 10403 10409	15 mmu
T24	NumberOfMissedCleavages 10443 10446	two
T25	Modification 10499 10531	carbamidomethylation of cysteine
A1	Modification T25 fixed
T26	Modification 10565 10584	oxidized methionine
A2	Modification T26 variable
T27	Modification 10586 10611	deamidation of asparagine
A3	Modification T27 variable
T28	Modification 10613 10668	pyro-glutamic acid modification at N-terminal glutamine
A4	Modification T28 variable
T29	Modification 10674 10697	hydroxylation of lysine
A5	Modification T29 variable
T30	Modification 10674 10690;10702 10709	hydroxylation of proline
A6	Modification T30 variable
T4	Disease 3722 3740	omental metastases
T8	OriginSiteDisease 3746 3778	high-grade serous ovarian cancer
T31	OriginSiteDisease 3780 3785	HGSOC
*	Equiv T8 T31
